- Home
- DMAC vs CDXS Comparison
DMAC vs CDXS Comparison
Compare DMAC & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CDXS
- Stock Information
- Founded
- DMAC 2000
- CDXS 2002
- Country
- DMAC United States
- CDXS United States
- Employees
- DMAC N/A
- CDXS N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- DMAC Health Care
- CDXS Industrials
- Exchange
- DMAC Nasdaq
- CDXS Nasdaq
- Market Cap
- DMAC 310.1M
- CDXS 254.3M
- IPO Year
- DMAC N/A
- CDXS 2010
- Fundamental
- Price
- DMAC $5.98
- CDXS $2.67
- Analyst Decision
- DMAC Strong Buy
- CDXS Buy
- Analyst Count
- DMAC 3
- CDXS 2
- Target Price
- DMAC $12.33
- CDXS $11.00
- AVG Volume (30 Days)
- DMAC 314.0K
- CDXS 1.3M
- Earning Date
- DMAC 08-12-2025
- CDXS 08-13-2025
- Dividend Yield
- DMAC N/A
- CDXS N/A
- EPS Growth
- DMAC N/A
- CDXS N/A
- EPS
- DMAC N/A
- CDXS N/A
- Revenue
- DMAC N/A
- CDXS $57,164,000.00
- Revenue This Year
- DMAC N/A
- CDXS $12.88
- Revenue Next Year
- DMAC N/A
- CDXS $21.64
- P/E Ratio
- DMAC N/A
- CDXS N/A
- Revenue Growth
- DMAC N/A
- CDXS N/A
- 52 Week Low
- DMAC $3.19
- CDXS $1.90
- 52 Week High
- DMAC $6.82
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- DMAC 65.09
- CDXS 42.87
- Support Level
- DMAC $5.90
- CDXS $2.74
- Resistance Level
- DMAC $6.18
- CDXS $3.06
- Average True Range (ATR)
- DMAC 0.39
- CDXS 0.23
- MACD
- DMAC 0.02
- CDXS -0.04
- Stochastic Oscillator
- DMAC 79.10
- CDXS 4.76
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.